MK-3475 vs. Docetaxel in second-line NSCLC (#540)
Laufzeit: 01.01.2013 - 31.12.2020
imported
Kurzfassung
A phase II/III randomized trial of two doses of MK-3475 (SCH900475) versus Docetaxel in previously treated subjects with non-small cell lung cancer
